The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are many issues surrounding the use of chemotherapy drugs in this population. In this interview, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, highlights the challenges of AML treatment in the elderly, and some of the options that can be offered to patients in which high dose chemotherapy will not prove beneficial, or patients who have a low tolerance to intensive chemotherapy. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
The complications of treating elderly patients with AML
